MedPath

SCICLONE PHARMACEUTICALS INTERNATIONAL (CAYMAN) DEVELOPMENT LIMITED

🇰🇾Cayman Islands
Ownership
Private
Established
1989-01-01
Employees
-
Market Cap
-
Website
http://www.sciclone.com/

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

Phase 1
Conditions
Advanced Solid Tumor
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2016-08-31
Last Posted Date
2018-04-25
Lead Sponsor
SciClone Pharmaceuticals International (Cayman) Development Limited
Target Recruit Count
75
Registration Number
NCT02884479
Locations
🇨🇳

Changhua Christian Hospital, Changhua County, Taiwan

🇨🇳

China Medical University & Hospital, Taichung, Taiwan

🇨🇳

National Cheng Kung University Hospital, Tainan City, Taiwan

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.